Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.


Journal

Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015

Informations de publication

Date de publication:
06 May 2024
Historique:
received: 17 10 2023
accepted: 19 03 2024
medline: 7 5 2024
pubmed: 7 5 2024
entrez: 6 5 2024
Statut: aheadofprint

Résumé

Fibroblast growth factor receptor (FGFR) alterations drive oncogenesis in multiple tumor types. Here we studied pemigatinib, a selective, potent, oral FGFR1-FGFR3 inhibitor, in the phase 2 FIGHT-207 basket study of FGFR-altered advanced solid tumors. Primary end points were objective response rate (ORR) in cohorts A (fusions/rearrangements) and B (activating non-kinase domain mutations). Secondary end points were progression-free survival, duration of response and overall survival in cohorts A and B, and safety. Exploratory end points included ORR of cohort C (kinase domain mutations, potentially pathogenic variants of unknown significance) and analysis of co-alterations associated with resistance and response. ORRs for cohorts A, B and C were 26.5%, 9.4% and 3.8%, respectively. Tumors with no approved FGFR inhibitors or those with alterations not previously confirmed to be sensitive to FGFR inhibition had objective responses. In cohorts A and B, the median progression-free survival was 4.5 and 3.7 months, median duration of response was 7.8 and 6.9 months and median overall survival was 17.5 and 11.4 months, respectively. Safety was consistent with previous reports. The most common any-grade treatment-emergent adverse events were hyperphosphatemia (84%) and stomatitis (53%). TP53 co-mutations were associated with lack of response and BAP1 alterations with higher response rates. FGFR1-FGFR3 gatekeeper and molecular brake mutations led to acquired resistance. New therapeutic areas for FGFR inhibition and drug failure mechanisms were identified across tumor types. ClinicalTrials.gov identifier: NCT03822117 .

Identifiants

pubmed: 38710951
doi: 10.1038/s41591-024-02934-7
pii: 10.1038/s41591-024-02934-7
doi:

Banques de données

ClinicalTrials.gov
['NCT03822117']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Babina, I. S. & Turner, N. C. Advances and challenges in targeting FGFR signalling in cancer. Nat. Rev. Cancer 17, 318–332 (2017).
doi: 10.1038/nrc.2017.8 pubmed: 28303906
Murugesan, K. et al. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations. ESMO Open 7, 100641 (2022).
doi: 10.1016/j.esmoop.2022.100641 pubmed: 36462464 pmcid: 9832751
Helsten, T. et al. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin. Cancer Res. 22, 259–267 (2016).
doi: 10.1158/1078-0432.CCR-14-3212 pubmed: 26373574
Xie, Y. et al. FGF/FGFR signaling in health and disease. Signal Transduct. Target Ther. 5, 181 (2020).
doi: 10.1038/s41392-020-00222-7 pubmed: 32879300 pmcid: 7468161
Incyte. PEMAZYRE (pemigatinib). Full prescribing information. (2022).
Janssen Biotech. BALVERSA (erdafitinib). Full prescribing information. (2022).
Taiho Oncology. LYTGOBI (futibatinib). Full prescribing information. (2023).
Pant, S. et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 24, 925–935 (2023).
doi: 10.1016/S1470-2045(23)00275-9 pubmed: 37541273
Subbiah, V. et al. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann. Oncol. 33, 522–533 (2022).
doi: 10.1016/j.annonc.2022.02.001 pubmed: 35176457
Meric-Bernstam, F. et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study. Cancer Discov. 12, 402–415 (2022).
doi: 10.1158/2159-8290.CD-21-0697 pubmed: 34551969
Schram, A. M. et al. First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors. J. Clin. Oncol. 39, TPS4165–TPS4165 (2021).
doi: 10.1200/JCO.2021.39.15_suppl.TPS4165
Nogova, L. et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study. J. Clin. Oncol. 35, 157–165 (2017).
doi: 10.1200/JCO.2016.67.2048 pubmed: 27870574
Liu, P. C. C. et al. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. PLoS ONE 15, e0231877 (2020).
doi: 10.1371/journal.pone.0231877 pubmed: 32315352 pmcid: 7313537
Sootome, H. et al. Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 80, 4986–4997 (2020).
Karkera, J. D. et al. Oncogenic characterization and pharmacologic sensitivity of activating fibroblast growth factor receptor (FGFR) genetic alterations to the selective FGFR inhibitor erdafitinib. Mol. Cancer Ther. 16, 1717–1726 (2017).
doi: 10.1158/1535-7163.MCT-16-0518 pubmed: 28416604
Subbiah, V. et al. RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations. Cancer Discov. 13, 2012–2031 (2023).
Zingg, D. et al. Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature 608, 609–617 (2022).
doi: 10.1038/s41586-022-05066-5 pubmed: 35948633 pmcid: 9436779
De Luca, A. et al. FGFR fusions in cancer: from diagnostic approaches to therapeutic intervention. Int. J. Mol. Sci. 21, 6856 (2020).
doi: 10.3390/ijms21186856 pubmed: 32962091 pmcid: 7555921
Nakamura, I. T. et al. Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer. NPJ Precis. Oncol. 5, 66 (2021).
doi: 10.1038/s41698-021-00204-0 pubmed: 34272467 pmcid: 8285406
Chen, H. et al. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol. Cell 27, 717–730 (2007).
doi: 10.1016/j.molcel.2007.06.028 pubmed: 17803937 pmcid: 2094128
Facchinetti, F. et al. Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer. Cancer Discov. 13, 1998–2011 (2023).
doi: 10.1158/2159-8290.CD-22-1441 pubmed: 37377403 pmcid: 10481128
Goyal, L. et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 7, 252–263 (2017).
doi: 10.1158/2159-8290.CD-16-1000 pubmed: 28034880
Lin, Q. et al. Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants. Commun. Chem. 5, 100 (2022).
doi: 10.1038/s42004-022-00718-z pubmed: 36698015 pmcid: 9814635
Wu, Q. et al. Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma. Clin. Cancer Res. 30, 198–208 (2023).
Pal, S. K. et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov. 8, 812–821 (2018).
doi: 10.1158/2159-8290.CD-18-0229 pubmed: 29848605 pmcid: 6716598
Silverman, I. M. et al. Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov. 11, 326–339 (2021).
doi: 10.1158/2159-8290.CD-20-0766 pubmed: 33218975
Yue, S. et al. FGFR-TKI resistance in cancer: current status and perspectives. J. Hematol. Oncol. 14, 23 (2021).
doi: 10.1186/s13045-021-01040-2 pubmed: 33568192 pmcid: 7876795
Necchi, A. et al. Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201. Ann. Oncol. 35, 200–210 (2024).
Chae, Y. K. et al. Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH trial (EAY131) subprotocol W. J. Clin. Oncol. 38, 2407–2417 (2020).
doi: 10.1200/JCO.19.02630 pubmed: 32463741 pmcid: 7367548
Papadopoulos, K. P. et al. A phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. Br. J. Cancer 117, 1592–1599 (2017).
doi: 10.1038/bjc.2017.330 pubmed: 28972963 pmcid: 5729432
Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21, 671–684 (2020).
doi: 10.1016/S1470-2045(20)30109-1 pubmed: 32203698 pmcid: 8461541
Cleary, J. M. et al. FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma. Cancer Discov. 11, 2488–2505 (2021).
doi: 10.1158/2159-8290.CD-20-1669 pubmed: 33926920 pmcid: 8690974
Goyal, L., Kongpetch, S., Crolley, V. E. & Bridgewater, J. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat. Rev. 95, 102170 (2021).
doi: 10.1016/j.ctrv.2021.102170 pubmed: 33735689
Krook, M. A. et al. Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. Mol. Cancer Ther. 19, 847–857 (2020).
doi: 10.1158/1535-7163.MCT-19-0631 pubmed: 31911531 pmcid: 7359896
Krook, M. A. et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb. Mol. Case Study 5, a004002 (2019).
doi: 10.1101/mcs.a004002
Varghese, A. M. et al. Noninvasive detection of polyclonal acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations. JCO Precis. Oncol. 5, PO.20.00178 (2021).
pubmed: 34250419 pmcid: 8232836
Lassman, A. B. et al. Infigratinib in patients with recurrent gliomas and FGFR alterations: a multicenter phase II study. Clin. Cancer Res. 28, 2270–2277 (2022).
doi: 10.1158/1078-0432.CCR-21-2664 pubmed: 35344029 pmcid: 9167702
Gile, J. J. et al. FGFR inhibitor toxicity and efficacy in cholangiocarcinoma: multicenter single-institution cohort experience. JCO Precis. Oncol. 5, PO.21.00064 (2021).
pubmed: 34778691 pmcid: 8575436
Farouk Sait, S. et al. Debio1347, an oral FGFR inhibitor: results from a single-center study in pediatric patients with recurrent or refractory FGFR-altered gliomas. JCO Precis. Oncol. 5, PO.20.00444 (2021).
pubmed: 34250399 pmcid: 8232545
Guercio, B. J. et al. Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience. Clin. Cancer Res. 29, 4586–4595 (2023).
doi: 10.1158/1078-0432.CCR-23-1283 pubmed: 37682528
Mody, K. et al. Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures. JCO Precis. Oncol. 6, e2100510 (2022).
doi: 10.1200/PO.21.00510 pubmed: 35675577 pmcid: 9200391
Rengan, A. K. & Denlinger, C. S. Robust response to futibatinib in a patient with metastatic FGFR-addicted cholangiocarcinoma previously treated using pemigatinib. J. Natl Compr. Cancer Netw. 20, 430–435 (2022).
doi: 10.6004/jnccn.2021.7121
Goyal, L. et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 9, 1064–1079 (2019).
doi: 10.1158/2159-8290.CD-19-0182 pubmed: 31109923 pmcid: 6677584
Javle, M. M. et al. Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: interim analysis. J. Clin. Oncol. 41, 539–539 (2023).
doi: 10.1200/JCO.2023.41.4_suppl.539
Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062–D1067 (2018).
doi: 10.1093/nar/gkx1153 pubmed: 29165669
Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Prec. Oncol. https://doi.org/10.1200/po.17.00011 (2017).
An Online Catalog of Human Genes and Genetic Disorders (OMIM, 2024); https://omim.org/
FoundationOne CDx. Technical Information (Foundation Medicine, 2023).
Predicine Inc. PredicineCARE (Predicine, 2023).

Auteurs

Jordi Rodón (J)

The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jrodon@mdanderson.org.

Silvia Damian (S)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Muhammad Furqan (M)

University of Iowa, Iowa City, IA, USA.

Jesús García-Donas (J)

Centro Integral Oncologico Clara Campal, Madrid, Spain.

Hiroo Imai (H)

Tohoku University Hospital, Sendai-Shi, Japan.

Antoine Italiano (A)

Institut Bergonié, Bordeaux, France.
Faculty of Medicine, University of Bordeaux, Bordeaux, France.

Iben Spanggaard (I)

Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.

Makoto Ueno (M)

Kanagawa Cancer Center, Yokohama, Japan.

Tomoya Yokota (T)

Shizuoka Cancer Center, Shizuoka, Japan.

Maria Luisa Veronese (ML)

Incyte International Biosciences Sàrl, Morges, Switzerland.

Natalia Oliveira (N)

Incyte International Biosciences Sàrl, Morges, Switzerland.

Xin Li (X)

Incyte Corporation, Wilmington, DE, USA.

Aidan Gilmartin (A)

Incyte Corporation, Wilmington, DE, USA.

Michael Schaffer (M)

Incyte Corporation, Wilmington, DE, USA.

Lipika Goyal (L)

Mass General Cancer Center, Harvard Medical School, Boston, MA, USA. lgoyal@stanford.edu.
Stanford Cancer Center, Stanford School of Medicine, Stanford, CA, USA. lgoyal@stanford.edu.

Classifications MeSH